Loss of the proapoptotic protein, Bim, breaks B cell anergy by Oliver, Paula M. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 3,  March 20, 2006  731–741  www.jem.org/cgi/doi/10.1084/jem.20051407
731 
The immune system must eliminate B cells 
that respond to self while providing protection 
against a broad range of foreign pathogens. In B 
cells, self-tolerance is achieved in several ways. 
Immature B cells that bind with high avidity 
to self-antigens they encounter are stimulated 
to rearrange their Ig genes again, with the goal 
of substituting genes coding for harmless Ig 
receptors for those coding for autoreactive Ig 
(1–8). Those B cells that fail to edit their recep-
tors away from autoreactivity are eliminated by 
clonal deletion (1, 8, 9). B cells that react with 
self-antigens with low avidity, or with soluble 
self-antigens, become anergic.
Several mouse models have been produced 
that aid the study of B cell anergy (10–14). Al-
though the B cells generated in these various 
models diff  er from each other in some aspects, 
they share some important properties. In most 
models, anergic B cells bear low levels of sur-
face IgM (mIgM) and appear to be blocked at 
the transitional 2 (T2) stage of B cell develop-
ment (12, 15–17). Thus, the cells are CD21low, 
CD23+, IgD+, CD93+, and IgMlow. Addition-
ally, the cells exhibit features of activated B 
cells, such as elevated CD86 and CD95, but 
other markers of activation are not apparent 
(18). Hence, anergic B cells have physical char-
acteristics marking them as recent bone mar-
row immigrants that are chronically stimulated 
by antigen.
Anergic B cells also have functional char-
acteristics that distinguish them from normal 
cells and are probably caused by chronic 
exposure to antigen. Amongst these are a 
  reduction in their ability to produce antibody 
in response to antigen and a shortened life 
  expectancy (10, 12, 13). Perhaps contributing 
to these two characteristics is an increased 
level of intracellular calcium in these cells at 
rest, coupled with an inability to raise their 
calcium levels in response to mIgM cross-
linking (12, 19).
The best-characterized model of B cell 
anergy is the so-called double transgenic (Dbl 
Tg) model in which mice express transgenes 
coding for soluble hen egg lysozyme (sHEL) 
and for an Ig receptor that can bind to sHEL 
(HEL-Ig; reference 10). This model allows 
comparison of anergic B cells in the Dbl Tg 
mice to their naive counterparts in mice 
    expressing only the HEL-Ig Tg and provides 
a system for stimulating cells in vitro with a 
well-defi  ned antigen.
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Although B cells that respond with high avidity to self-antigen are eliminated early in their 
development, many autoreactive B cells escape elimination and are tolerized later in their 
lives via anergy. Anergic B cells are unresponsive to antigen and die prematurely. It has been 
suggested that the proapoptotic protein, Bim, controls the fate of anergic B cells. To test 
this idea, mice lacking Bim were crossed with mice that express soluble hen egg lysozyme 
and whose B cells bear receptors specifi  c for the protein. In Bim+/+ mice these B cells are 
anergic and die rapidly. If the mice lack Bim, however, the B cells live longer, are more 
mature, respond to antigen, and secrete anti–hen egg lysozyme antibodies. This break of 
tolerance is not due to expression of endogenous B cell receptors, nor is it dependent on 
T cells. Rather, it appears to be due to a reduced requirement for the cytokine BAFF. Normal 
B cells require BAFF both for differentiation and survival. Bim−/− B cells, on the other 
hand, require BAFF only for differentiation. Therefore, autoreactive B cells are allowed to 
survive if they lack Bim and thus accumulate suffi  cient signals from differentiating factors 
to drive their maturation and production of autoantibodies.
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Early work in this model suggested that anergic B cells 
might have shortened life spans because they were killed by 
CD4 cells expressing Fas and interacting with Fas ligand on 
the surface of the anergic cells (20). Later work, however, 
suggests that the life span of anergic B cells and autoreactive 
B cells destined for death may be mainly under the control of 
members of the Bcl-2 family (21). Overexpression of Bcl-2 
or Bcl-xl protects autoreactive B cells from death, although 
they remain anergic (15, 22, 23). Anergic B cells contain 
higher levels of the proapoptotic Bcl-2–related protein, Bim, 
than wild-type cells do (24), and absence of Bim inhibits the 
death of autoreactive B cells and prolongs the survival of 
HEL-reactive B cells in vivo (25). In theory, once B cells are 
rendered anergic, they should remain so, providing antigen 
levels are maintained. However, the longer their life 
expectancy, the greater the risk that an anergic B cell will 
“break through” and respond to antigen, so presumably this 
shortened life expectancy of anergic B cells, controlled by 
Bcl-2–related proteins, is important to the maintenance of 
B cell tolerance.
The survival and diff  erentiation of B cells is aff  ected by 
the cytokine BAFF and this cytokine also aff  ects the tolerance 
status of B cells. In animals that contain a mixed population 
of anergic and naive B cells, anergic B cells do not compete 
very well for BAFF and remain unresponsive (17, 24). 
However, in the absence of competitor naive B cells, overex-
pression of BAFF converts anergic B cells into cells that are 
no longer unresponsive and that secrete autoantibody. Based 
on these in vivo observations, it has been proposed that, to 
stay alive and maintain function, anergic cells may require 
more BAFF than wild-type cells do.
Collectively, these results suggest some intersection be-
tween the eff  ects of Bcl-2–related proteins and BAFF on the 
survival and function of anergic B cells. To address this, we 
created Bim−/− Dbl Tg mice. Loss of Bim increased B cell 
numbers in such animals and the B cells that were present 
were more mature, based on expression of IgM and CD21. 
These mature B cells responded to HEL in vitro and secreted 
antibody in vivo, indicating a breach of tolerance. This break 
of tolerance did not depend on T cells or coexpression of 
  endogenous B cell receptors (BCRs). Rather, our data 
  suggested that loss of Bim allowed the B cells to survive 
  independently of their normal survival factor, BAFF. This 
longer life expectancy allowed the B cells to accumulate dif-
ferentiation signals from factors such as BAFF. Once diff  er-
entiated, the B cells were able to respond normally to antigen 
and secrete antigen-specifi  c Ig. Thus, in normal mice, Bim 
prevents maturation and activity of autoreactive anergic 
B cells by decreasing their life expectancy and exposure to 
  diff  erentiation-inducing signals.
RESULTS
Lack of Bim increases the number of B cells in Dbl Tg mice
B cell numbers are governed by the frequency with which 
they enter the periphery, their proliferation, and the length of 
time they survive. Dbl Tg mice have 20–35% fewer splenic B 
cells than either their naive (HEL-Ig) or wild-type (C57BL6) 
counterparts. It has been shown that this is the result of a 
shortened B cell life span (26–28). BCR signaling induces 
B cell death both directly, by activating Bim (25), and also 
indirectly, by increasing the cell’s requirement for cytokines, 
such as BAFF, that promote survival of the cells (24).
Bim is involved in the deaths of B cells deprived of cyto-
kine-mediated survival signals and of B cells exposed to anti-
gen (25, 29). Thus, we reasoned that Bim could play an 
important role in the death of anergic B cells. To fi  nd out 
whether this is so, we crossed Bim−/− mice to Dbl Tg animals 
and analyzed the resulting off  spring. Spleens and lymph nodes 
from Bim−/− Dbl Tg mice were visibly larger than those in 
their Bim+/+ counterparts. Microscopic evaluation revealed 
an increased size of the white pulp regions (Fig. 1 A), and 
these regions of the spleen contained expanded populations 
of both B and T cells (Fig. 1 B). This latter result was con-
fi  rmed by fl  ow cytometry, which showed that the spleens of 
Bim−/− Dbl Tg mice contained increased numbers of B cells, 
exceeding even those of wild-type controls (Fig. 1 C). This 
phenomenon became more pronounced in older mice. Al-
though we observed signifi  cant variability, on average Bim−/− 
Dbl Tg spleens contained  2.5 times more B cells than did 
the spleens of Bim+/+ Dbl Tg control animals (P < 0.003).
Bim−/− Dbl Tg B cells are not tolerant
Bim−/− mice have high levels of circulating autoantibodies 
and die prematurely of antibody complex–mediated disease 
(29). It has been shown that autoreactive B cells in Bim−/− 
mice are less likely to die during negative selection in the 
bone marrow (25). However, this observation cannot ac-
count for the high serum autoantibody levels in Bim−/− mice 
because the autoreactive cells should become anergic and 
hence unable to secrete autoantibody. Thus, the presence of 
autoantibody in Bim−/− mice suggests that the mechanisms 
maintaining anergy are defective in such animals. To fi  nd out 
if this was the case, we measured serum anti-HEL antibody 
titers in various types of mice expressing or lacking Bim.
Mice that did not express HEL-Ig had virtually no soluble 
anti-HEL antibodies, whether or not the mice also expressed 
Bim. On the other hand, single Tg mice, expressing only 
HEL-Ig, contained high levels of anti-HEL antibody in their 
sera. Again, this result was independent of Bim expression. 
As has been reported previously, Dbl Tg Bim+/+ mice con-
tained very little serum anti-HEL, refl  ecting the anergic sta-
tus of their B cells. Dbl Tg mice lacking Bim, on the other 
hand, contained almost as high levels of serum anti-HEL as 
mice expressing just HEL-Ig (Fig. 2 A; P < 0.001). Thus, the 
absence of Bim inhibited anergy in Dbl Tg mice.
The antibody in the Bim−/− mice could have been se-
creted by plasma cells in the bone marrow. To fi  nd out if this 
was possible, we stained bone marrow cells from these and 
control mice, and compared plasma cell numbers. As shown 
in Fig. 2 B, and as reported previously (30), Bim+/+ Dbl Tg 
mice contained very few early diff  erentiating  (B220hi, 
CD138+) or mature (B220lo, CD138+) plasma cells by JEM VOL. 203, March 20, 2006  733
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  comparison with their HEL-Ig counterparts. Bim−/− Dbl Tg 
mice, on the other hand, contained as many plasma cells of 
both types as Bim+/+ or Bim−/− HEL-Ig mice did.
Based on these data, we suggest that loss of Bim allows B 
cells to escape anergy as witnessed by the increased number 
of bone marrow plasma cells and by the high levels of circu-
lating autoantibody in Bim−/− Dbl Tg animals.
B cells in Bim−/− Dbl Tg mice are more mature 
than their anergic counterparts
After B cells leave the bone marrow, they continue to ma-
ture, passing from the T1 stage through the T2 stage to be-
come naive follicular (FO) B cells (31). Previous examination 
of B cells from Bim+/+ Dbl Tg mice showed that the aner-
gic B cells in these mice do not mature beyond the late T2 
stage, as demonstrated by their expression of low levels of 
CD21 and high levels of CD23 (Fig. 3, A and B; reference 
15). These anergic cells also bear low levels of IgM, presum-
ably caused by chronic exposure to antigen. On the whole, 
Bim+/+ Dbl Tg spleens contain fewer FO B cells and have 
only a small number of marginal zone (MZ) B cells, as de-
fi  ned by FO localization or surface expression of CD21 and 
CD23 (FO cells are CD21int and CD23high, whereas MZ cells 
are CD21high and CD23low).
Figure 1.  Loss of Bim increases B cell number in Dbl Tg mice and 
improves survival. (A) Spleens and lymph nodes were isolated from 
Bim+/+ and Bim−/− Dbl Tg animals as well as from their naive HEL-Ig Tg 
counterparts. Tissues were sectioned and stained with hematoxylin and 
eosin. Tissue images were taken using a 10× objective. (B) Sections of 
frozen spleen were stained with antibodies to TCR (blue), mIg H+L (red), 
and MadCam-1 (green) and examined by fl  uorescence microscopy. Exam-
ples from two different experiments are shown. (C) The total number of 
B cells per spleen was determined by fl  ow cytometry measuring the per-
centage of total B220+ cells.
Figure 2.  B cells from Bim−/− Dbl Tg mice are not tolerant. 
(A) Sera from 8–24-wk-old mice were analyzed by ELISA for reactivity to 
HEL. The level of reactivity for each sample was normalized to that of a 
known HEL-Ig Tg Bim+/+ control sample. Each dot represents an individual 
mouse. Lines represent mean values for each genotype. (B) Bone marrow 
cells were isolated from the various genotypes and plasma cells were 
analyzed by fl  ow cytometry for expression of B220 and CD138 (syndican). 
Early differentiating (B220hi, CD138+ cells) and mature (B220lo, CD138+) 
plasma cells were gated to determine their frequency. (C) Mature plasma 
cell numbers/femur were calculated, and the mean and standard devia-
tions of the numbers derived from three to four animals from each geno-
type are shown. *, P < 0.05; **, P < 0.001.734  LOSS OF BIM BREAKS B CELL ANERGY | Oliver et al.
The presence of plasma cells and serum antibody in 
Bim−/− Dbl Tg mice suggested that the B cells in these mice 
were developing beyond the T2 cell stage. Accordingly, we 
analyzed spleen and lymph node B cells for markers charac-
teristic of maturation. Bim−/− Dbl Tg mice were found to 
contain a population of cells with increased levels of CD21 
and mIgM (Fig. 3, A and B), indicating that these cells had 
matured beyond the T2 stage. These cells were found to have 
varying levels of CD23 expression, suggesting that both FO 
and MZ populations had increased in number.
The elevated levels of CD21 and mIgM on the Bim−/− 
Dbl Tg B cells suggested that the cells were not anergic. 
Therefore, the cells were tested for their ability to fl  ux calcium 
in response to antigen. We found that the cells that expressed 
elevated levels of CD21 fl  uxed calcium in response to HEL 
signifi  cantly better than either the CD21low cells from the 
same mice or their Bim+/+ anergic counterparts (Fig. 3 C).
Collectively, these data show that there is a population of 
B cells in the Bim−/− Dbl Tg animals that mature, even in 
the presence of autoantigen. These cells display increased 
CD21 and respond to HEL almost as well as their naive 
counterparts; therefore, they are not anergic.
The loss of tolerance is not due to expression 
of endogenous receptor
We wished to fi  nd out how loss of Bim allowed autoreactive 
B cells to survive and avoid anergy. One possibility is that 
lack of Bim reduces the effi   ciency of allelic exclusion. If this 
were so, Bim−/− B cells expressing anti-HEL might be 
allowed to rearrange their endogenous Ig genes more often 
than Bim+/+ anti-HEL B cells do. Because simultaneous ex-
pression of two diff  erent antigen receptors has been shown to 
allow autoreactive B cell clones to progress through develop-
ment (32), such a scenario would account for the fact that 
Bim−/− B cells are not anergic in Dbl Tg mice.
The anti-HEL Ig in Dbl Tg mice is IgMa and IgDa, 
whereas the endogenous μ heavy chain alleles in Dbl Tg 
mice backcrossed to C57BL6 is IgMb. Cells that avoided 
allelic exclusion in these mice could therefore be identifi  ed 
by their expression of mIgMb. B cells from Dbl Tg mice that 
did or did not express Bim were stained with anti-IgDa and 
anti-IgMb. We chose to analyze IgDa because, unlike IgMa, 
its cell surface expression is not reduced in anergic cells.
There was no increase in the percentage of cells express-
ing an endogenous IgMb receptor in Bim−/− Dbl Tg mice 
versus Bim+/+ Dbl Tg controls. Likewise, we did not ob-
serve considerable numbers of cells expressing both   receptors 
simultaneously (Fig. 4). This analysis was also   applied to cells 
from older mice to see if the emergence of these cells takes 
time to detect. Again, we found no diff  erence  between 
Bim+/+ or Bim−/− mice (not depicted). Thus, we conclude 
that the break of tolerance observed in these mice is not due 
to dual usage of both the Tg and endogenous heavy chains.
T cells are not required for Bim−/− B cells to break tolerance
It is thought that T cell help might break B cell anergy (30, 
33, 34). Because Bim aff  ects T as well as B cell tolerance, it is 
possible that B cells escape anergy in Bim−/− Dbl Tg mice 
because they receive help from T cells that escaped tolerance 
and not because loss of Bim aff  ects the B cells directly. To test 
this idea, Bim−/− Dbl Tg mice were crossed to mice lacking 
TCRα. The resultant progeny were intercrossed to produce 
mice lacking both Bim and TCRα and expressing either or 
both of the HEL-Ig and sHEL transgenes. We compared 
Figure 3.  B cells from Bim−/− Dbl Tg mice are more mature than 
B cells from their Bim+/+ anergic counterparts. (A and B) Cells were 
isolated from the spleens of HEL-Ig Tg or Dbl Tg mice that were Bim+/+ 
or Bim−/−. The cells were analyzed by fl  ow cytometry for expression of 
(A) CD21 and IgMa, and (B) CD23 and IgMa. (C) Spleen cells from mice of 
the various genotypes were loaded with Indo-1 and stimulated with 1 μg/ml 
HEL. Samples were gated on B220 and either CD21low (dashed lines) or 
CD21hi (solid lines) populations and analyzed for Ca2+ fl  ux over time. All 
Ca2+ fl  ux histograms are plotted on the same scale. Arrows indicate when 
HEL was added to the samples. Data are representative of two indepen-
dent experiments.JEM VOL. 203, March 20, 2006  735
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these to similar mice expressing Bim. Spleens from these 
mice were analyzed for the presence of B cells expressing 
  increased levels of IgMa and CD21 as compared with naive 
controls, as indicators of loss of anergy. Surprisingly, we 
found that Bim−/− B cells escaped tolerance induced by an-
ergy even in the absence of T cells (Fig. 5). B cell numbers in 
Dbl Tg TCRα−/− mice lacking Bim were substantially 
higher than in cohorts expressing Bim (5.5 × 107 vs. 3.8 × 
107 B220+ cells/spleen, respectively). Furthermore, the B 
cells from Bim−/− Dbl Tg animals lacking T cells expressed 
higher levels of both IgM and CD21 (Fig. 5 C). Likewise, ti-
ters of serum antibodies against HEL were unaff  ected by the 
lack of T cells, with Bim−/− Dbl Tg TCRα−/− mice con-
taining the same high levels of anti-HEL as their TCRα+/+ 
counterparts (Fig. 5 D).
These data indicate that T cells do not play a prominent 
role in the escape of Bim−/− B cells from anergy.
Serum HEL levels are not lower in Bim−/− Dbl Tg mice
Peripheral tolerance is broken in Bim−/− B cells in the 
  absence of T cell help. Thus, the defect that allows B cells to 
break anergy appears to be cell intrinsic. One possible expla-
nation is that the increased number of B cells in the Dbl Tg 
Bim−/− animals reduces the amount of available HEL in the 
serum below a threshold required to maintain anergy. To test 
this, we measured the amount of HEL in these mice that was 
available to bind B cells. A sandwich ELISA was used to do 
this. The HEL in the mouse sera was captured using the 
  HyHEL9 anti-HEL monoclonal antibody. This antibody rec-
ognizes an epitope on HEL that is not seen by the anti-HEL 
Tg BCR (35–37). We then measured the amount of cap-
tured HEL that was available to bind the anti-HEL Tg recep-
tor   using biotinylated-HyHEL10, an antibody that recognizes 
the same epitope as the anti-HEL Tg BCR (35), and   detected 
the complex with streptavidin–horseradish peroxidase (HRP). 
As shown in Fig. 6, levels of available HEL did not diff  er 
  signifi  cantly between mice expressing or lacking Bim, al-
though the available HEL in Dbl Tg Bim−/− sera tended to 
be slightly lower than that in their Bim+/+ counterparts. The 
concentration of HEL in serum required to induce anergy has 
been reported previously to be >0.5 ng/ml and less than the 
9.5 ng/ml reported in Dbl Tg mice (27, 38, 39), and the con-
centration of HEL in the Bim−/− Dbl Tg averaged 8.3 ng/ml.
If a lowering of the available HEL was required to break B 
cell tolerance, the Bim−/− Dbl Tg mice that express the high-
est levels of HEL should remain tolerant. This turns out not 
to be the case. In the three Bim−/− Dbl Tg mice that showed 
the highest levels of available HEL (Fig. 6 A), 10–20% of the 
splenic B cells were not anergic and expressed higher levels of 
CD21 and IgM.
The idea that lower HEL levels aff  ected tolerance was tested 
in another way by analyzing the amount of HEL bound to 
B cells in Bim−/− Dbl Tg mice and Bim+/+ Dbl Tg controls. To
measure the amount of HEL bound to the B cell surface, we 
used the HyHEL9 monoclonal antibody, the antibody that 
does not compete for binding to HEL with the HEL-Ig Tg re-
ceptor. For the sake of comparison, and as a positive control for 
HEL binding, we also analyzed HEL-Ig Tg B cells that had 
been incubated with soluble HEL before the analysis. As shown 
in Fig. 6 B, HEL-Ig Tg B cells preincubated with HEL bound 
plenty of HyHEL9. There was a signifi  cant amount of HEL 
bound to the B cells in Dbl Tg Bim−/− mice. These levels were 
not signifi  cantly diff  erent from those on B cells from Dbl Tg 
Bim+/+ animals (mean fl  uorescence intensity of 11.2 vs. 13.4).
Although these data clearly show that there is available 
HEL in the serum of Dbl Tg Bim−/− mice (Fig. 6 A) and that 
HEL is bound to B cells isolated from these mice (Fig. 6 B), 
we have not ruled out the possibility that the amount of 
available HEL drops below a threshold such that newly 
emerging B cells do not see enough HEL to be fully aner-
gized. To test this, we isolated HEL-Ig Tg B cells from a 
Bim+/+ mouse, labeled the cells with CFSE to ensure that we 
could distinguish them from the B cells in the recipients, and 
transferred them into a Dbl Tg Bim−/− mouse. We per-
formed this transfer during the period that B cells in the re-
cipient mouse were beginning to break tolerance (8–10 wk 
of age). To evaluate whether or not the transferred cells were 
binding antigen, we compared the levels of surface IgM on 
these cells with those on HEL-Ig Tg B cells and Dbl Tg 
B cells. Levels of IgM on these transferred cells fell to those on
Dbl Tg Bim+/+ or Dbl Tg Bim−/− cells (Fig. 6 C). Thus, the 
levels of HEL in Dbl Tg Bim−/− mice are suffi   cient to reduce 
surface IgM levels to those of tolerized cells.
Collectively, these data suggest that the break in B cell 
tolerance in Bim−/− mice is not caused by a reduction in 
available HEL.
Figure 4.  Expression of endogenous Ig genes does not contribute 
to the loss of anergy of Bim−/− Dbl Tg B cells. Cells were isolated 
from the spleens of mice of the various genotypes. B220+ cells were ana-
lyzed by fl  ow cytometry for expression of IgDa (Tg BCR), and IgMb (endog-
enous BCR) was determined. These data shown are representative of four 
animals from each genotype analyzed in two independent experiments.736  LOSS OF BIM BREAKS B CELL ANERGY | Oliver et al.
Bim−/− Dbl Tg B cells survive in the absence of BAFF
Normal B cells depend upon BAFF both for survival and 
maturation as indicated by the fact that BAFF−/− animals 
contain normal numbers of immature B cells but are de-
void of mature FO and MZ populations (40, 41). Anergic 
B cells are also highly dependent on BAFF. Overexpres-
sion of BAFF in mice allows the survival and maturation of 
B cells that would otherwise be anergic, and also allows 
the cells to break tolerance and secrete antibody (17, 24). 
The observation that anergic B cells do not compete well 
with normal cells for BAFF suggests that these cells are 
more dependent than wild-type cells on this cytokine. 
These   experiments did not demonstrate, however, whether 
BAFF eff  ected loss of anergy by increasing the life expec-
tancy of anergic B cells or by stimulating their maturation, 
or both.
To fi  nd out which feature of anergic B cells was aff  ected 
by BAFF and the relative concentrations of BAFF involved, 
we isolated B cells from HEL-Tg or Dbl Tg mice that did or 
did not express Bim and cultured the cells without or with 
HEL with titrated concentrations of BAFF. 4 d later we mea-
sured the percentage of B cells that survived. BAFF does not 
induce B cell proliferation in vitro (42), so the eff  ects ob-
served must have been due to the response of the B cells in 
Figure 5.  T cells are not required for loss of B cell tolerance in 
Bim−/− Dbl Tg mice. (A–C) Cells were isolated from the spleens of mice 
of the various genotypes. (A) Cells were stained with antibodies against 
B220 and TCRβ to confi  rm the absence of T cells. (B and C) B220+ cells 
were analyzed for expression levels of (B) IgMa and (C) CD21. Anti-HEL 
serum antibody titers were measured using ELISAs. Data from TCRα+/+ 
mice were obtained at the same time as that from TCRα−/− mice using 
the HEL-Ig Tg sample used previously for normalization. The data from 
TCRα+/+ mice are from Fig. 2 A and are shown again here for the sake of 
comparison. Each dot represents an individual mouse. Lines represent the 
mean values for each genotype. Mice were between 8 and 24 wk of age. 
Each genotype contained animals spanning this age range.JEM VOL. 203, March 20, 2006  737
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the cultures directly to BAFF and not to preferential expan-
sion of a particular B cell subset.
Some Bim+/+ HEL-Ig B cells survived the 4 d of cul-
ture, but their survival was considerably improved by cul-
ture with increasing concentrations of BAFF. The survival 
of the B cells was compromised if they had been exposed to 
HEL in mice because barely any Dbl Tg B cells survived 
the culture, and very few of these cells were rescued by 
even high concentrations of BAFF (Fig. 7 A). These eff  ects 
were more pronounced if the cells were cultured with HEL 
(Fig. 7 B).
In the absence of Bim, many more B cells survived in 
culture. B cells from Bim−/− Dbl Tg mice survived almost as 
well as B cells from HEL-Tg animals (Fig. 7 C), so prior ex-
posure to antigen had little eff  ect on the life expectancy of 
these B cells. Likewise, exposure to antigen in vitro had little 
eff  ect on the survival of the cells (Fig. 7 D). BAFF did not in-
crease survival of the cells (Fig. 7, C and D).
Thus, as expected, exposure to antigen in the absence of 
helper factors such as BAFF did indeed cause the rapid death of 
wild-type cells and even more rapid death of anergic cells. As 
predicted by others, anergic B cells do indeed require higher 
concentrations of BAFF to survive than normal B cells do. Bim 
must play a key role in this antigen-mediated killing because 
Bim−/− B cells die slowly, regardless of antigen signaling.
Bim−/− Dbl Tg B cells do not mature in the absence of BAFF
We examined the maturation status, as measured by CD21 
and CD93 levels, of the B cells that survived in the cultures 
described above. Culture with BAFF resulted in higher 
levels of CD21 on all the populations of surviving cells (Fig. 8, 
A–D). However, anergic Bim+/+ B cells from Dbl Tg mice 
needed much more BAFF to mature into high expression of 
CD21 than nonanergic Bim+/+ B cells, and this eff  ect was 
also manifest by the addition of HEL to the cultures (Fig. 8, 
A and B). This was less obviously true for Bim−/− B cells. In 
Figure 6.  Dbl Tg Bim+/+ and Bim−/− mice contain similar amounts 
of HEL in their serum. (A) Sera from 8–24-wk-old mice were analyzed 
by ELISA for levels of available HEL. The level of reactivity for each sample 
was compared with a titration of HEL (of known concentration) analyzed 
within the same plate. Closed circles represent Bim−/− mice, and open 
circles represent Bim+/+ animals. Each dot refl  ects an individual mouse. 
(B) The B cells were incubated with biotinylated HyHEL9, a monoclonal 
anti-HEL antibody that binds to HEL on a different site than the Tg HEL-Ig 
receptor. HyHEL binding was detected with streptavidin-PE. Fluorescence 
observed after staining was used to measure background fl  uorescence. 
The staining of HEL-Ig Tg B cells with HEL added ex vivo is shown for 
comparison. (C) IgM levels were measured on B cells isolated from the 
various genotypes as well as on HEL-Ig Tg Bim+/+ B cells that were trans-
ferred 24 h before analysis into a Dbl Tg Bim−/− mouse. (B and C) Mice 
were 8–10 wk of age at the time of analysis. Error bars represent the 
standard deviations of the results from three mice per genotype.
Figure 7.  Bim−/− B cells do not depend upon BAFF for survival. 
(A–D) B cells were isolated from mice of the indicated genotypes and 
cultured for 4 d in the presence of various concentrations of BAFF. Sur-
vival was determined by forward and side scatter analysis using fl  ow 
cytometry. (B and D) B220+ B cells were isolated from mice of the indi-
cated genotypes and cultured in the presence or absence of 100 ng/ml 
HEL as well as in increasing concentrations of BAFF. Data represent the 
average of cells from three mice of each genotype. Error bars show stan-
dard deviations from the mean.738  LOSS OF BIM BREAKS B CELL ANERGY | Oliver et al.
the absence of HEL in the cultures, Bim−/− B cells matured 
effi   ciently in response to BAFF, whether or not the cells had 
been exposed to HEL in vivo (Fig. 8 C). On the other hand, 
the addition of HEL to their culture medium caused the 
Bim−/− B cells to require more BAFF to mature, and this ef-
fect was somewhat more pronounced for cells from Dbl Tg 
mice (Fig. 8 D).
Culture of cells in BAFF had little eff  ect on expression 
of CD93 (AA4.1, 493, and C1qRp), a phenotypic marker of 
immature B cells (42, 43), on the anti-HEL Tg B cells from 
mice that lacked HEL (Fig. 8, E and G). This is because these 
cells were already too mature to express CD93. On the other 
hand, cells from Dbl Tg animals expressed high levels of 
CD93, which fell during culture in BAFF (Fig. 8, F and H).
Culture of anti-HEL Tg B cells in the presence of HEL 
  increased CD93 levels even further (Fig. 8, E–H). The addi-
tion of BAFF to the cultures abrogated this. Thus, exposure 
to BAFF can change the phenotype of anergic cells, allowing 
them to lose expression of immature markers, like CD93, and 
gain expression of mature B cell markers, such as CD21.
In these experiments, Bim−/− Dbl Tg B cells responded 
to lower levels of BAFF than the Bim+/+ Dbl Tg control 
cells. The maturation of Bim−/− Dbl Tg B cells in response 
to low levels of BAFF could be explained in two ways. It 
might suggest that Bim aff  ects maturation as well as survival 
of the B cells. On the other hand, this observation could be 
the result of reduced antigen exposure in vivo. The high lev-
els of circulating antibody observed in these animals could 
bind sHEL and thus eff  ectively lower the amount of antigen 
available to bind the B cells (as shown in Fig. 6 D). Thus, un-
like their wild-type counterparts from Dbl Tg mice, these 
Dbl Tg B cells from Bim−/− animals are not anergic and 
therefore respond to BAFF just like normal naive cells do.
Anergic B cells need higher concentrations of BAFF 
to survive than differentiate
The data from Figs. 7 and 8 (A–H) were plotted in a diff  er-
ent way to allow comparison of the BAFF dose response for 
survival versus diff  erentiation of Bim+/+ B cells. Nonanergic 
B cells from HEL-Tg mice had about the same dose   response 
Figure 8.  Bim−/− B cells require BAFF to differentiate. (A–H) B 
cells were isolated from mice of the indicated genotypes and cultured 
for 4 d in the presence of increasing concentrations of BAFF. CD21 or 
CD93 expression was determined by flow cytometry and plotted using 
the mean fluorescence intensity of each sample. Open circles repre-
sent 100 ng/ml HEL added at the beginning of each culture. Closed 
circles indicate that no HEL was added. (I and J) The samples described 
above were plotted differently to allow for comparison of the BAFF 
dose response for both survival and differentiation (CD21 expression) 
of the Bim+/+ B cells. Data represent the average of three samples 
from mice of each genotype. Error bars show standard deviations 
from the mean.JEM VOL. 203, March 20, 2006  739
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to BAFF for survival and maturation, with a midpoint be-
tween 1 and 10 ng/ml BAFF for both functions (Fig. 8 I). 
Anergic B cells from Dbl Tg mice showed evidence of dif-
ferentiation at similarly low levels of BAFF, with signifi  cant 
diff  erentiation at 1 ng/ml BAFF. However, the survival of 
these cells required much higher concentrations of BAFF, 
with virtually no eff  ect seen until BAFF levels were above 
10 ng/ml (Fig. 8 J).
Collectively, these results show that anergic B cells re-
quire about the same concentrations of BAFF for maturation 
as wild-type B cells do. However, for survival, anergic B cells 
need more BAFF than their wild-type equivalents do. Bim−/− 
B cells do not need BAFF at any level for survival; therefore, 
their only requirement for BAFF is as a maturation factor, a 
role BAFF can satisfy at quite low levels. Thus, these results 
account for the fact that lack of Bim allows B cells to escape 
anergy. Bim−/− B cells do not need BAFF for survival and 
need only relatively low levels of BAFF to mature.
DISCUSSION
Anergic B cells have several properties that prevent them 
from producing autoantibodies. They respond poorly to an-
tigen, as defi  ned by relatively small increases in intracellular 
calcium, fail to enter cell cycle, and are unable to secrete an-
tibody. They also have shorter half-lives in vivo than normal 
B cells. They do not fully mature and their development is 
arrested at the T2 stage of B cell maturation. They do not 
migrate properly and cannot make their way to the sites 
where B cells normally reside, splenic follicles and MZs (21). 
It is not clear which of these features contributes most to the 
absence of autoantibodies in healthy animals, and it is also not 
clear whether these properties are controlled by the same or 
diff  erent phenomena within the anergic cells.
To fi  nd out which properties are crucial for the mainte-
nance of anergy, investigators have examined each separately 
for its eff  ects. In almost all cases, B cells expressing high levels 
of the antiapoptotic proteins Bcl-2 or Bcl-xl have lengthened 
life spans but are still anergic in the presence of chronic self-
antigen (22, 23, 44). In one model system, in which B cells 
express the transgenes for an insulin-specifi  c Ig, the B cells 
are anergic even though they fully mature and migrate to fol-
licles and MZs in spleens (14). In another set of experiments, 
investigators forced anergic B cells to migrate abnormally by 
adjusting their expression of CXCR5 and CCR7, yet the 
B cells remained short lived and anergic (21). Thus, anergy is
not controlled in B cells by their shortened life expectancy, 
early maturational status, or abnormal location, at least as in-
dividual properties.
Of the several phenomena known to break B cell anergy 
(45–47), the most striking is overexposure to the cytokine 
BAFF. In normal animals, BAFF promotes the survival and 
maturation of B cells at and beyond the T2 stage (40, 41). 
Overexpression of BAFF causes mice to develop autoanti-
bodies and allows B cells that would normally be anergic in 
Dbl Tg mice to mature, live longer, migrate to sites such as 
the MZ, and secrete autoantibodies (17, 24). However, aner-
gic B cells do not compete well with normal B cells for BAFF 
(24), which may account for the fact that in animals with 
normal levels of BAFF, anergic cells do not break tolerance. 
Collectively with the data discussed above, these results sug-
gest that several features of anergic B cells prevent their mat-
uration into autodestructive cells.
Here we show that absence of the proapoptotic protein 
Bim also allows B cells that would otherwise be anergic to 
mature and secrete autoantibodies. This seems to be allowed 
because of the diff   erent requirements of anergic cells for 
BAFF for survival versus maturation. Thus, normal B cells 
have about the same sensitivity to BAFF for survival and for 
maturation. However, anergic cells require more BAFF to 
mature than normal B cells do and, as suggested in the past, 
require even higher concentrations of BAFF to keep them-
selves alive. Normal and anergic B cells lacking Bim no lon-
ger need BAFF to keep themselves alive. They do still need 
BAFF to diff  erentiate, but, for Bim−/− cells, the dose re-
sponse to BAFF for maturation of anergic and normal cells is 
about the same. Thus, lack of Bim promotes loss of anergy 
because Bim-defi  cient B cells no longer need BAFF to sur-
vive and have about the same sensitivity to BAFF for matura-
tion as normal B cells do.
With these results in mind, it is interesting to wonder 
why overexpression of the antiapoptotic protein Bcl-2 does 
not similarly always interrupt B cell anergy. In the model of 
B cell tolerance in which B cell Ig is specifi  c for class I MHC, 
overexpression of Bcl-2 prevents the deletion of the autore-
active cells and, depending on the site at which the class I is 
expressed, allows antibody production (23). In mice in which 
B cells are specifi  c for soluble-stranded DNA, high levels of 
Bcl-2 cause anergic B cells to mature but not secrete autoan-
tibody (44). In a model in which B cells are normally deleted 
in the bone marrow, heightened expression of Bcl-2 allows 
B cells to mature, only to become anergic (22). Of course over-
expression of Bcl-2 is not quantitatively equivalent to com-
plete absence of Bim. Even as a transgene, the Bcl-2 may not 
be overexpressed in quantities suffi   cient to overcome the ac-
tion of normal levels of Bim. Thus, lack of Bim may shift the 
life expectancy and dose response to BAFF of anergic B cells 
more toward normality than overexpression of Bcl-2 does.
MATERIALS AND METHODS
Mice. Homozygous Bim−/− mice were bred from mice provided by 
A. Strasser (Walter and Eliza Hall Institute of Medical Research, Melbourne, 
Australia; reference 29). TCRα−/− mice were originally obtained from The 
Jackson Laboratory (48). HEL-Ig Tg and sHEL Tg mice were also purchased 
from The Jackson Laboratory (10). All mice were backcrossed at least seven 
generations to C57BL/6 mice (The Jackson Laboratory). All mice were 
maintained under pathogen-free conditions in the Biological Resource Cen-
ter, National Jewish Medical and Research Center, and were 8–16 wk old at 
the beginning of each experiment unless otherwise noted. The protocols used 
were in accordance with the guidelines drafted by National Jewish Medical 
and Research Center and Institutional Animal Care and Use Committee.
Cell sorting and fl  ow cytometry analysis. For surface staining, cell sus-
pensions were incubated for more than 20 min on ice with anti–mouse 
FcR-γ2, 2.4G2 to prevent nonspecifi   c binding of antibodies to the Fc 740  LOSS OF BIM BREAKS B CELL ANERGY | Oliver et al.
  receptors on cells. Cells were resuspended in PBS containing 1% BSA and 
0.1% sodium azide and incubated with an optimal amount of labeled anti-
bodies as noted. Alternatively, cells were incubated for 30 min with antibod-
ies directly diluted in 2.4G2. Antibodies used for these experiments included 
anti-CD21/CD35-FITC, anti–CD23-PE, anti-CD138, anti–IgM-APC, 
anti–IgMa-PE, anti–IgDa-PE, anti-IgMb, and anti–B220-APC or anti-Cy-
Chrome (all from BD Biosciences). The monoclonal hamster anti–mouse 
anti-TCRβ coupled to Oregon Green, Ham-597, was described previously 
(49). Biotinylated anti-CD93 was originally described elsewhere (43). After 
incubation with antibodies, cells were sorted using a MoFlo machine (Dako-
Cytomation) or analyzed on a FACSCalibur machine. Data analysis was per-
formed using CELLQuest (BD Biosciences) and FloJo (TreeStar) software.
Cell transfer. 5 × 106 B220+ B cells purifi  ed by MoFlo cell sorting (Dako-
Cytomation) were labeled with CFSE. In brief, 107 cells were incubated at 
37° for 10 min in 2.5 μM CFSE and then washed. Cells were then trans-
ferred into the tail vein of recipient mice.
Calcium mobilization. To measure free intracellular calcium concentra-
tion ([Ca2+]i), cells were loaded with Indo-1AM (Invitrogen), labeled with 
anti–B220-APC and CD21-Fitc, resuspended at 106 cells/ml in DMEM, 
and analyzed using fl  ow cytometry. After the baseline was established, cells 
were stimulated with 1 μg/ml HEL. Mean [Ca2+]i was evaluated over time 
using the LSR cytometer (Becton Dickinson) and analyzed using FloJo soft-
ware (TreeStar).
Cell culture. Cells were isolated from spleens and a single cell suspension 
was prepared, depleted of erythrocytes using buff  ered ammonium chloride, 
and washed twice in DMEM. B220+ B cells were isolated by MoFlo cell 
sorting (DakoCytomation) and then incubated in DMEM containing 10% 
FCS (Oatlanta Biologicals) as well as 100 U/ml penicillin, 100 μg/ml strep-
tomycin, 50 μg/ml gentamicin, 2 mM l-glutamine, 1 mM sodium pyruvate, 
and 50 μM 2-ME.
HEL binding assay. To analyze the amount of HEL bound to BCR on the 
cell surface, spleen cells were isolated and incubated on ice with a biotinylated 
HyHEL9 anti-HEL antibody diluted in 2.4G2. Cells were washed and then 
incubated in streptavidin-PE. As a positive control for HEL binding, HEL-Ig 
Tg spleen cells were incubated with 100 ng/ml HEL before analysis.
ELISA. Sera were collected from mice and analyzed for HEL-specifi  c anti-
body titers or available HEL using ELISA. To measure HEL-specifi  c anti-
bodies, plates were coated with 5 μg/well HEL diluted in PBS, washed fi  ve 
times, and then blocked with 30% FBS in PBS for at least 1 h at room tem-
perature. Plates were then washed and serial dilutions of sera and standards 
were added. Plates were incubated for 1 h at room temperature and then 
washed. The assays were incubated for 1 h at room temperature with HRP-
labeled rat anti–mouse IgM. To measure available HEL, plates were coated 
with HyHEL9 and then blocked using 30% FCS. The HyHEL9 antibody 
recognizes HEL on a diff  erent epitope than that seen by the anti-HEL Tg 
BCR (37). Each serum was serially diluted and added to plate. After incuba-
tion with serum, plates were washed and then biotinylated HyHEL10 anti-
body was added. The HyHEL10 antibody recognizes the same epitope on 
HEL as the anti-HEL Tg BCR (35). Antibody binding was detected using 
streptavidin-HRP. To quantify the amount of available HEL, HEL was ti-
trated in the absence of serum and detected using the method described 
above. Samples were compared with readings from this known standard. 
Plates were developed with PNPP for colorimetric detection.
Histology and immunohistochemistry. Mice were killed and lymph 
nodes and spleens were embedded in Tissue-Tek O.C.T. (Fisher Scientifi  c), 
frozen in dry ice–cooled 2-methylbutane, and stored at −70°C until 
  sectioning. Spleens were cut on a cryostat and successive sections of 6–8 mm 
were thaw-mounted on slides. Sections were air-dried, acetone-fi  xed for 
5 min, and stored at −70°C. After thawing, slides were rehydrated with 5% 
normal goat serum in PBS for 10 min, and the spleens were stained for 
30 min at room temperature. The reagents used were anti–mouse MadCam-1 
(BD Biosciences), anti-Ig (H+L), and anti-TCRβ.
For histology, spleens and lymph nodes were fi  xed in 4% paraformalde-
hyde, paraffi   n embedded, and stained with hematoxylin and eosin.
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